| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.02 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.063 | 0.03 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.065 | 0.03 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.03 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |